The team
Gerry A.F. Nicolaes
Ph.D., Co-Founder, CEO & CSO
g.nicolaes@hillmarkbiopharma.com
Gerry Nicolaes, Current Chief Executive Officer and Chief Scientific Officer was trained as a biochemist at the Utrecht University (the Netherlands). He has a background in clinically oriented biochemistry, structural bioinformatics and molecular discovery. He has frequently bridged the in vitro, in silico and in vivo worlds to bring basic observations and inventions to the lead compound stage. He made contributions to the discovery and development of small molecules, peptides and biologicals. His work has resulted in several patent applications, one of which is currently in a clinical development stage.
Kanin Wichapong
Ph.D., Co-Founder, CTO and Project Manager
k.wichapong@hillmarkbiopharma.com
Kanin Wichapong, Chief Technology Officer & Project Manager, is the scientist in charge of the computer-aided molecular design efforts at Hillmark. His research lines focus on the application of computer-based methods (such as virtual screening, molecular docking, molecular dynamics simulations, and binding free energy calculations) in drug discovery and development. His major research achievements are for example, the development of SKY peptide to interrupt CCL5-HNP1 interactions (Sci. Trans. Med., 2015), and HIPe (Nature, 2019) & CHIP (Circulation, 2021) peptide to neutralize cytotoxicity of histones.
